Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > Acumen Capital raised Viemed to 14 Canadian from 12 Canadian
View:
Post by LongTerm3 on May 05, 2022 10:48am

Acumen Capital raised Viemed to 14 Canadian from 12 Canadian

This works out to US 10.97 from $9.36.

From the report:

" Conference Call Highlights. Growth expected to be driven by: (1) acquisitions, (2) hospital partnerships, (3) solutions providers (staffing and behavioural health), and (4) expansion of national payor contracts. Bad debt expense typically peaks in the first quarter and is expected to be in the historic range for the full year (5-6%). Additional details are on Page 2. 

Recommendation. With the operating environment close to pre-pandemic levels, we believe VMD’s organic growth will return to near historic levels (core revenue growth forecast to be 20% in 2022). VMD’s valuation remains compelling at current levels, trading at 4.1x 2023 EV/EBITDA vs. the larger home medical equipment peers trading at 14.4x. We maintain a BUY Rating with a $14.00 Target Price (up from $12.00 due to our revised estimates."
Comment by stockfy on May 12, 2022 11:25am
Thanks for this.